Burning Rock Biotech (BNR) Accumulated Expenses (2019 - 2026)

As of Dec 31, 2025, Burning Rock Biotech posted Accumulated Expenses of $11.56 million, up 37.9% from the prior year.

• Accumulated Expenses has a five-year compound annual growth rate of -2.0% (years ended Dec 2020 to Dec 2025).
• By year, Accumulated Expenses came in at $8.39 million in the year ended Dec 31, 2024 (-16.3%), $10.02 million in the year ended Dec 31, 2023 (-60.2%), $25.2 million in the year ended Dec 31, 2022 (+25.6%) and $20.07 million in the year ended Dec 31, 2021 (+56.6%).
• The figure for the quarter ended Jun 30, 2026 ranks as the lowest quarterly Accumulated Expenses since the quarter ended Dec 31, 2023.
• Year over year, Accumulated Expenses gained in two of the last eight quarters, with an average decline of 5.3%.
• The high point for year-over-year Accumulated Expenses in five years was the quarter ended Mar 31, 2022 (growth of 77.9%); the low point was the quarter ended Jun 30, 2024 (a decline of 45.0%).
• Per Business Quant data, the three quarters before the quarter ended Jun 30, 2026 came in at $10.93 million (quarter ended Mar 31, 2026), $11.4 million (quarter ended Dec 31, 2025) and $10.82 million (quarter ended Sep 30, 2025).